BOI Stock Overview
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||€42.15|
|52 Week High||€48.00|
|52 Week Low||€32.60|
|1 Month Change||3.95%|
|3 Month Change||3.95%|
|1 Year Change||4.33%|
|3 Year Change||7.53%|
|5 Year Change||-52.32%|
|Change since IPO||811.95%|
Recent News & Updates
Boiron (EPA:BOI) Has Re-Affirmed Its Dividend Of €0.95
Boiron SA ( EPA:BOI ) will pay a dividend of €0.95 on the 3rd of June. This means the annual payment will be 2.3% of...
|BOI||FR Pharmaceuticals||FR Market|
Return vs Industry: BOI underperformed the French Pharmaceuticals industry which returned 17.6% over the past year.
Return vs Market: BOI exceeded the French Market which returned -6.3% over the past year.
|BOI Average Weekly Movement||4.3%|
|Pharmaceuticals Industry Average Movement||5.3%|
|Market Average Movement||6.0%|
|10% most volatile stocks in FR Market||10.1%|
|10% least volatile stocks in FR Market||3.5%|
Stable Share Price: BOI is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: BOI's weekly volatility (4%) has been stable over the past year.
About the Company
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders.
Boiron Fundamentals Summary
|BOI fundamental statistics|
Is BOI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BOI income statement (TTM)|
|Cost of Revenue||€212.51m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||1.63|
|Net Profit Margin||6.27%|
How did BOI perform over the long term?See historical performance and comparison
2.3%Current Dividend Yield
Does BOI pay a reliable dividends?See BOI dividend history and benchmarks
|Boiron dividend dates|
|Ex Dividend Date||Jun 01 2022|
|Dividend Pay Date||Jun 03 2022|
|Days until Ex dividend||6 days|
|Days until Dividend pay date||8 days|
Does BOI pay a reliable dividends?See BOI dividend history and benchmarks
Is Boiron undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BOI (€42.15) is trading below our estimate of fair value (€119.09)
Significantly Below Fair Value: BOI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BOI is poor value based on its Price-To-Earnings Ratio (25.8x) compared to the French Pharmaceuticals industry average (23.5x).
PE vs Market: BOI is poor value based on its Price-To-Earnings Ratio (25.8x) compared to the French market (16.1x).
Price to Earnings Growth Ratio
PEG Ratio: BOI is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: BOI is good value based on its Price-To-Book Ratio (1.4x) compared to the FR Pharmaceuticals industry average (2.4x).
How is Boiron forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BOI's forecast earnings growth (17.9% per year) is above the savings rate (0.3%).
Earnings vs Market: BOI's earnings (17.9% per year) are forecast to grow faster than the French market (11.9% per year).
High Growth Earnings: BOI's earnings are forecast to grow, but not significantly.
Revenue vs Market: BOI's revenue (4.8% per year) is forecast to grow slower than the French market (5.8% per year).
High Growth Revenue: BOI's revenue (4.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BOI's Return on Equity is forecast to be low in 3 years time (8.8%).
How has Boiron performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BOI has a large one-off gain of €7.7M impacting its December 31 2021 financial results.
Growing Profit Margin: BOI's current net profit margins (6.3%) are higher than last year (5.1%).
Past Earnings Growth Analysis
Earnings Trend: BOI's earnings have declined by 27.1% per year over the past 5 years.
Accelerating Growth: BOI's earnings growth over the past year (9%) exceeds its 5-year average (-27.1% per year).
Earnings vs Industry: BOI earnings growth over the past year (9%) underperformed the Pharmaceuticals industry 9%.
Return on Equity
High ROE: BOI's Return on Equity (5.4%) is considered low.
How is Boiron's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: BOI's short term assets (€452.4M) exceed its short term liabilities (€158.2M).
Long Term Liabilities: BOI's short term assets (€452.4M) exceed its long term liabilities (€80.7M).
Debt to Equity History and Analysis
Debt Level: BOI has more cash than its total debt.
Reducing Debt: BOI's debt to equity ratio has reduced from 2% to 0.7% over the past 5 years.
Debt Coverage: BOI's debt is well covered by operating cash flow (910.8%).
Interest Coverage: BOI earns more interest than it pays, so coverage of interest payments is not a concern.
What is Boiron current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Future Dividend Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: BOI's dividend (2.25%) is higher than the bottom 25% of dividend payers in the French market (1.72%).
High Dividend: BOI's dividend (2.25%) is low compared to the top 25% of dividend payers in the French market (5.04%).
Stability and Growth of Payments
Stable Dividend: BOI's dividend payments have been volatile in the past 10 years.
Growing Dividend: BOI's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (58.3%), BOI's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (128.6%), BOI's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Valérie Lorentz-Poinsot (52 yo)
Ms. Valerie Lorentz-Poinsot serves as General Manager of Boiron SA since January 1, 2019 and served as its Deputy General Manager since July 01, 2011 and also served as its Director of Development. Ms. Lor...
CEO Compensation Analysis
Compensation vs Market: Valérie's total compensation ($USD900.07K) is above average for companies of similar size in the French market ($USD528.35K).
Compensation vs Earnings: Valérie's compensation has been consistent with company performance over the past year.
Experienced Management: BOI's management team is considered experienced (3.3 years average tenure).
Experienced Board: BOI's board of directors are seasoned and experienced ( 15.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Boiron SA's employee growth, exchange listings and data sources
- Name: Boiron SA
- Ticker: BOI
- Exchange: ENXTPA
- Founded: 1932
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €736.732m
- Shares outstanding: 17.48m
- Website: https://www.boiron.fr
Number of Employees
- Boiron SA
- 2, avenue de l’Ouest Lyonnais
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/25 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.